It is Not a Curse! It is Neurofibromatosis 1 (NF1): A Case Report from Rural Kenya
DOI:
https://doi.org/10.54536/ajmsi.v3i1.2709Keywords:
Neurofibromatosis 1, NF1, Von Recklinghausen Disease, Café-Au-Lait Macules, Neurofibromas, Skin Freckles, KenyaAbstract
Neurofibromatosis 1 (NF1) is an autosomal dominant genetic disorder caused by mutations in the NF1 gene, with near complete penetrance and variable clinical presentation. Patients classically have café-au-lait macules, neurofibromas, skin freckles, and Lisch nodules, among other multisystemic features. Long-term management in a multidisciplinary team focuses on surveillance and treating complications. NF1 is a rare disease in Kenya, often leading to myths and misconceptions about its nature, especially among rural communities. We present a classical case from rural Kenya whose diagnosis was delayed by a belief that it was the result of a curse. We aim to highlight the importance of making this diagnosis and its linkage to a long-term care plan within a primary health care setting.
Downloads
References
DiMario, F. J., Jr., & Ramsby, G. (1998). Magnetic Resonance Imaging Lesion Analysis in Neurofibromatosis Type 1. Archives of Neurology, 55(4), 500-505. https://doi.org/10.1001/archneur.55.4.500
Ferner, R. E., Huson, S. M., Thomas, N., Moss, C., Willshaw, H., Evans, D. G., Upadhyaya, M., Towers, R., Gleeson, M., Steiger, C., & Kirby, A. (2007). Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet, 44(2), 81-88. https://doi.org/10.1136/jmg.2006.045906
Gutmann, D. H., Ferner, R. E., Listernick, R. H., Korf, B. R., Wolters, P. L., & Johnson, K. J. (2017). Neurofibromatosis type 1. Nat Rev Dis Primers, 3, 17004. https://doi.org/10.1038/nrdp.2017.4
Lee, T. J., Chopra, M., Kim, R. H., Parkin, P. C., & Barnett-Tapia, C. (2023). Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis, 18(1), 292. https://doi.org/10.1186/s13023-023-02911-2
Legius, E., Messiaen, L., Wolkenstein, P., Pancza, P., Avery, R. A., Berman, Y., Blakeley, J., Babovic-Vuksanovic, D., Cunha, K. S., Ferner, R., Fisher, M. J., Friedman, J. M., Gutmann, D. H., Kehrer-Sawatzki, H., Korf, B. R., Mautner, V. F., Peltonen, S., Rauen, K. A., Riccardi, V., . . . Plotkin, S. R. (2021). Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med, 23(8), 1506-1513. https://doi.org/10.1038/s41436-021-01170-5
Masocco, M., Kodra, Y., Vichi, M., Conti, S., Kanieff, M., Pace, M., Frova, L., & Taruscio, D. (2011). Mortality associated with neurofibromatosis type 1: a study based on Italian death certificates (1995-2006). Orphanet J Rare Dis, 6, 11. https://doi.org/10.1186/1750-1172-6-11
Moutal, A., Yang, X., Li, W., Gilbraith, K. B., Luo, S., Cai, S., François-Moutal, L., Chew, L. A., Yeon, S. K., Bellampalli, S. S., Qu, C., Xie, J. Y., Ibrahim, M. M., Khanna, M., Park, K. D., Porreca, F., & Khanna, R. (2017). CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. Pain, 158(12), 2301-2319. https://doi.org/10.1097/j.pain.0000000000001002
Ochola, E. A., Karanja, D. M. S., & Elliott, S. J. (2021). The impact of Neglected Tropical Diseases (NTDs) on health and wellbeing in sub-Saharan Africa (SSA): A case study of Kenya. PLoS Negl Trop Dis, 15(2), e0009131. https://doi.org/10.1371/journal.pntd.0009131
Ortonne, N., Wolkenstein, P., Blakeley, J. O., Korf, B., Plotkin, S. R., Riccardi, V. M., Miller, D. C., Huson, S., Peltonen, J., Rosenberg, A., Carroll, S. L., Verma, S. K., Mautner, V., Upadhyaya, M., & Stemmer-Rachamimov, A. (2018). Cutaneous neurofibromas: Current clinical and pathologic issues. Neurology, 91(2 Suppl 1), S5-s13. https://doi.org/10.1212/wnl.0000000000005792
Plotkin, S. R., Bredella, M. A., Cai, W., Kassarjian, A., Harris, G. J., Esparza, S., Merker, V. L., Munn, L. L., Muzikansky, A., Askenazi, M., Nguyen, R., Wenzel, R., & Mautner, V. F. (2012). Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One, 7(4), e35711. https://doi.org/10.1371/journal.pone.0035711
Plotkin, S. R., Messiaen, L., Legius, E., Pancza, P., Avery, R. A., Blakeley, J. O., Babovic-Vuksanovic, D., Ferner, R., Fisher, M. J., Friedman, J. M., Giovannini, M., Gutmann, D. H., Hanemann, C. O., Kalamarides, M., Kehrer-Sawatzki, H., Korf, B. R., Mautner, V. F., MacCollin, M., Papi, L., . . . Evans, D. G. (2022). Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genet Med, 24(9), 1967-1977. https://doi.org/10.1016/j.gim.2022.05.007
Prada, C. E., Rangwala, F. A., Martin, L. J., Lovell, A. M., Saal, H. M., Schorry, E. K., & Hopkin, R. J. (2012). Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr, 160(3), 461-467. https://doi.org/10.1016/j.jpeds.2011.08.051
Sanagoo, A., Jouybari, L., Koohi, F., & Sayehmiri, F. (2019). Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study. BMC Neurol, 19(1), 123. https://doi.org/10.1186/s12883-019-1338-y
Stewart, D. R., Korf, B. R., Nathanson, K. L., Stevenson, D. A., & Yohay, K. (2018). Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med, 20(7), 671-682. https://doi.org/10.1038/gim.2018.28
Tamura, R. (2021). Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. Int J Mol Sci, 22(11). https://doi.org/10.3390/ijms22115850
Van Es, S., North, K. N., McHugh, K., & De Silva, M. (1996). MRI findings in children with neurofibromatosis type 1: a prospective study. Pediatr Radiol, 26(7), 478-487. https://doi.org/10.1007/bf01377205
Vernimmen, V., Paulussen, A. D. C., Dreesen, J., van Golde, R. J., Zamani Esteki, M., Coonen, E., van Buul-van Zwet, M. L., Homminga, I., Derijck, A., Brandts, L., Stumpel, C., & de Die-Smulders, C. E. M. (2023). Preimplantation genetic testing for Neurofibromatosis type 1: more than 20 years of clinical experience. Eur J Hum Genet, 31(8), 918-924. https://doi.org/10.1038/s41431-023-01404-x
Wilding, A., Ingham, S. L., Lalloo, F., Clancy, T., Huson, S. M., Moran, A., & Evans, D. G. (2012). Life expectancy in hereditary cancer predisposing diseases: an observational study. J Med Genet, 49(4), 264-269. https://doi.org/10.1136/jmedgenet-2011-100562
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Vonwicks C. Onyango, Nicholas M. Mutuma, Samuel M. Gachie, Boniface Mutiso, Nicholas Auma, William C. Fryda MD
This work is licensed under a Creative Commons Attribution 4.0 International License.